In vivo switching of human melanoma cells between proliferative and invasive states by Hoek, K S et al.
TITLE 
In vivo switching of human melanoma cells between proliferative and invasive states. 
 
AUTHORS 
Keith S. Hoek1*, Ossia Eichhoff1, Natalie C. Schlegel1, Udo Döbbeling1, Nikita Kobert1, Leo 
Schaerer2, Silvio Hemmi3, and Reinhard Dummer1. 
 
AFFILIATIONS 
1Department of Dermatology, University Hospital of Zurich, Zurich 8091, Switzerland.   
2Dermatohistopathologischen Gemeinschaftspraxis, 88048 Friedrichshafen, Germany.   
3Institute of Molecular Biology, University of Zurich, Zurich 8057, Switzerland. 
 
*Correspondence to keith.hoek@usz.ch, +41 432553978 (phone), +41 432554418 (fax). 
 
ABSTRACT 
Transcription profiling of melanoma cell lines previously identified two transcription 
signatures predicted to respectively correspond with proliferation and invasion.  Here we 
identify Microphthalmia-associated transcription factor (Mitf) as a useful marker for signature 
membership and demonstrate that knockdown of Mitf alters signature phenotype.  
Proliferative and invasive signature cell lines were used in xenograft experiments and 
resulting tumors were assessed for Mitf expression by immunohistochemistry.  All tumors, 
irrespective of the signature type injected, displayed immunohistochemical evidence for both 
proliferative and invasive signature melanoma cells.  These data indicate that melanoma cells 
undergo bi-directional transcriptional signature switching in vivo which is likely regulated by 
local microenvironmental conditions.  The findings challenge previous models of melanoma 
progression which evoke one-way changes in gene expression. 
 SIGNIFICANCE 
Current molecular models for melanoma link linear gene expression change with clinical 
progression, a paradigm which has informed nearly all molecular studies of the disease.  We 
build on previous experiments, where we showed that melanoma cells may present with either 
of two distinct transcription signatures respectively related to proliferative and invasive 
aspects of the disease, to demonstrate that in vivo these signatures are interchangeable rather 
than fixed states.  We construct a new model which describes melanoma progression as a 
result of melanoma cells oscillating between transcriptional programs of proliferation and 
invasion. 
INTRODUCTION 
Metastatic stage melanoma is an aggressive disease that few patients survive for more than 
two years.  Compounding this, scores of clinical trials testing different adjuvant therapies 
have brought no significant improvement in the survival outlook for these patients (Sasse et 
al., 2007).  One possible explanation for this is that melanoma is a heterogeneous collection of 
different cells, with differences between them sufficient that some cells are missed by targeted 
therapies.  The variety of phenotypic and behavioral features melanomas present range from 
differing organ specificities during metastasis to changes in characteristics of motility and 
invasion (Fidler and Kripke, 1977).  Furthermore, examination of melanoma tissues reveal 
various morphologies, from assorted macroscopic lesional structures to an array of 
microscopic cellular forms, which often complicate assessments of diagnosis and prognosis 
(Levene, 1980).  Additionally, immunohistochemical staining regularly yields equally 
heterogeneous results.  While most melanoma lesions will stain for a number of melanocytic 
markers, this is not necessarily true for all the melanoma cells within a given lesion (Banerjee 
and Harris, 2000).  Finally, DNA microarray examination of different lesions and melanoma 
cell line collections reveal among them consistent taxonomies of genomic aberrations and 
transcriptional signatures (Curtin et al., 2005; Haqq et al., 2005; Hoek et al., 2006).  The 
source of heterogeneity is thought to rest in the combination of how melanoma cells respond 
to different microenvironments and the reciprocal influence of their own molecular states.  
This was an idea first conceptualized to a significant degree in the “seed and soil” model put 
forward by Stephen Paget after his observation that particular cancer cells demonstrated 
tumorigenic preference for certain tissues over others (Paget, 1889; Ribatti et al., 2006).  By 
comparison, our current molecular models for melanoma progression are comparatively 
homogenous.  Generally accepted hypotheses concerning molecular contributions towards 
melanoma pathobiology assume the reasonable premise that progression of the disease is 
driven by a steady evolution of molecular changes within the cell (Miller and Mihm, 2006).  It 
is in this context that concepts of gene modification or gene expression change are invoked to 
provide the framework upon which molecular studies into melanoma are carried out. 
 
Of particular recent interest has been the activity of the microphthalmia-associated 
transcription factor Mitf in regulating melanoma cell proliferation.  In normal melanocytes 
Mitf is critical for melanocytic differentiation, expression of melanogenic enzymes and 
upregulating cyclin-dependent kinase inhibitors to drive cell cycle exit (Carreira et al., 2005; 
Loercher et al., 2005; Steingrimsson et al., 2004).  However, in melanoma Mitf is required for 
proliferation and has been identified as a “lineage survival” factor prone to amplification 
(Carreira et al., 2006; Du et al., 2004; Garraway et al., 2005).  While the contrast in the 
activities of Mitf in normal and transformed cells remains unexplained, there is little doubt 
concerning its central role in melanoma biology. 
 
We recently explored heterogeneity of gene expression in melanoma cells, following earlier 
work performed by Bittner and coworkers who suggested that there may be specific 
transcriptional signatures delineating melanoma cell subgroups (Bittner et al., 2000).  We 
characterized two different transcription signatures for melanoma cell lines which, based on 
known functions of the genes involved, defined their respective contributions to metastatic 
potential as either proliferative or invasive (Hoek et al., 2006).  We further hypothesized that 
the transcription signatures represent distinct yet interchangeable states regulated by changes 
in signaling from the microenvironment.  Critically, Mitf expression is a central feature of the 
proliferative signature and is absent from the invasive form.  Others’ in vitro work concerning 
MITF gene regulation have corroborated the hypothesis that its expression is important for 
differentiating between proliferative and invasive states (Carreira et al., 2006).  To test the 
validity of the proliferative signature we examined Mitf’s role in the proliferative signature 
phenotype and compared the in vivo tumorigenicity of these cells against those with an 
invasive signature.  At the same time we used immunohistochemistry to monitor Mitf and the 
Ki67 antigen in the resulting tumors to provide evidence of in vivo switching between 
signatures. 
 
RESULTS 
Proliferative And Invasive Transcription Signatures Yield Distinct In Vitro Phenotypes 
To study the in vivo tumorigenic behaviour of melanoma cell lines with different 
transcriptional signatures, we selected pairs of proliferative and invasive signature melanoma 
cell lines based on previous genome-wide transcription profiling experiments (Hoek et al., 
2006).  We performed supervised hierarchical clustering of the samples using normalized 
signal intensity data of 105 genes tightly linked to signature (Figure 1A).  Earlier experiments 
in which monolayers of cells were observed for surface motility had shown that proliferative 
signature lines were significantly less motile than invasive signature lines (Hoek et al., 2006).  
Also, the different signature cell types were subjected to TGF challenge and this showed that 
proliferative signature cells were significantly more susceptible to TGF-mediated growth 
inhibition than invasive signature cells (Hoek et al., 2006).  We performed additional in vitro 
motility and proliferation experiments to expand this range of in vitro characterizations.  Cell 
growth experiments showed a significant (p < 0.001) difference in proliferation rates between 
proliferative and invasive signature cell lines (Figure 1B).  On the other hand, invasive 
signature cell lines plated at subconfluent densities on 8m microporous transwell filters 
migrated in significantly (p < 0.001) higher numbers towards the lower chamber over 16 
hours than identically plated proliferative cell lines (Figure 1C).  With these experiments we 
therefore concluded that signature assignments given to cell lines according to their gene 
expression signature correlate appropriately with in vitro data in the context of our model.  
This model implies that the signatures differ through activation of gene expression patterns by 
different signal pathways and predicts that in vivo conditions may influence signaling to effect 
signature switching. 
 
 
 
Immunohistochemistry Identifies A Signature-Specific Marker 
Given that it was our intention to use immunohistochemistry to follow cell signatures in vivo, 
we selected markers according to their signature specificity.  Previous analysis indicated that 
Mitf mRNA and protein levels are high in proliferative signature lines and at low or 
undetectable levels in invasive signature samples (Hoek et al., 2006).  We confirmed this by 
performing immunohistochemistry on paraffin-embedded cultures of proliferative and 
invasive signature melanoma lines.  Immunohistochemical staining of the different signature 
cell line pellets with anti-Mitf antibodies showed that in proliferative signature cell lines 93% 
of cells were positive for nuclear staining for Mitf while the invasive signature cell lines 
showed 0% positivity (Figure 2).  We have not found immunohistochemical markers which 
unequivocally identify invasive melanoma cells.  This is principally because these cells have 
downregulated all of the genes responsible for the melanocytic phenotype observable in 
proliferative signature melanoma cells.  Instead, the differential in proliferation rates for the 
different signatures indicated that a general proliferation marker may be useful for 
immunohistochemical identification of signature type in vivo.  While examination of 
previously published gene expression data shows that between transcriptional signature types 
there is no significant differential in the expression of mRNA encoding the proliferation 
marker Ki67 antigen, the significant difference in in vitro proliferation rates suggest that Ki67 
antigen is likely to show a difference at the protein level.  Accordingly, staining for Ki67 
antigen showed that 94% of proliferative signature cells and 45% of invasive signature cells 
had positively stained nuclei (Figure 2).  These results indicate that Mitf is a good marker for 
specific identification of proliferative signature cells and that Ki67 antigen is a suitable 
marker for identifying regions undergoing differential rates of proliferation.  
 
 
 
Mitf Expression Reflects Signature Phenotype 
In order to confirm that Mitf expression is functionally linked to signature phenotype we used 
siRNA to knockdown Mitf protein levels and assessed the effects in vitro.  One in vitro 
characteristic which distinguishes between proliferative and invasive signature melanoma 
cells is a differential in susceptibility to TGF-mediated inhibition of proliferation, with 
proliferative signature cells being more sensitive to TGF than invasive signature cells(Hoek 
et al., 2006).  Because proliferative signature cells express Mitf and invasive signature cells 
do not, we hypothesized that Mitf expression mediated the growth inhibitory effect of TGF 
on proliferative signature cells.  We performed anti-Mitf siRNA knockdown experiments in a 
proliferative signature melanoma line and confirmed knockdown by Western blot analyses 
(Figure 3A).  We found that Mitf-depletion from proliferative signature melanoma cells made 
them less susceptible to TGF-mediated growth inhibition (Figure 3B), showing that Mitf 
mediates the growth inhibitory effect of TGF.  This demonstrates that Mitf function is 
closely linked to the relationship between transcription signature and in vitro phenotype, 
confirming it as a useful in vivo marker for identifying different signature cells. 
 
Proliferative Cells Form Fast Growing Tumors Sooner Than Invasive Cells. 
To test the relationship of cell line signature assignments with in vivo behaviour we 
performed subcutaneous injection of cell lines into the flanks of immunocompromised mice 
and recorded tumor growth characteristics.  We found that proliferative melanoma lines 
consistently formed tumors about two weeks after being injected into the flanks of athymic 
nude mice, while invasive lines took considerably longer to begin tumorigenesis (Figure 2A).  
The length of time taken for growth initiation, measured as the time at which tumor volume 
exceeds 100 mm3, was 14 ± 3 days for proliferative signature cells, and 59 ± 11 days for 
invasive signature cells (p < 0.001).  These data provide in vivo evidence for the significance 
of a proliferative signature in melanoma cells as predicted by in vitro experiments.  The 
proliferative signature seeded tumors all initiated growth at nearly the same time point.  
Contrasting this, initiation times for the invasive signature seeded tumors was spread over a 
wider period.  This suggests to us that proliferative signature seeded initiation is less 
dependent on microenvironment variation than invasive signature seeded initiation. 
 
Tumors Derived From Proliferative Or Invasive Lines Are Indistinguishable. 
Because both transcription signature melanoma cell types yielded tumors we were interested 
in examining these for signature-specific differences.  Upon excision the tumors were stained 
for Mitf and Ki67 antigen expression to look at the distributions of these markers.  Tumors 
derived from invasive signature cell lines, which did not stain for Mitf, revealed melanoma 
cells with nuclei which were Mitf-positive and melanoma cells with nuclei which were Mitf-
negative (Figures 5A-E).  Tumors derived from proliferative signature cell lines, which 
stained for Mitf, showed the same patterning of stained and unstained melanoma cell nuclei 
(Figures 5F-J).  Additionally, in all tumors examined we found that Mitf-stained nuclei tended 
to concentrate within the peripheral margins of the tumors.  We found that Ki67 antigen 
staining patterns were similarly indistinguishable in tumors derived from proliferative or 
invasive signature lines.  Conversely, it was apparent that tumor regions showing Mitf-
positive nuclei were also enriched for Ki67-positive nuclei.  These findings showed that 
tumors seeded with invasive or proliferative signature cell lines were not distinguishable and 
that homogeneous in vitro staining patterns yielded strikingly heterogeneous patterns in vivo, 
showing that signature patterns of melanoma cells change bi-directionally in vivo. 
DISCUSSION 
A feature of current models for gene expression involvement in melanoma progression is their 
explicitly one-way nature.  It is typical to present a graph in which gene expression changes 
proceed concomitantly with stage progression, where a gene either increases or decreases 
expression as the disease evolves through clinically recognized stages to metastasis (Miller 
and Mihm, 2006).  However, models of this design do not account for the broad molecular 
heterogeneity which is apparent in melanoma.  Immunohistochemical studies do not support 
the idea that the expression of certain genes is switched irrevocably on or off during the 
course of the disease, starting from one state at transformation and ending at another once 
metastasis has been achieved.  Instead it is clear that, in many melanoma cells within a given 
lesion, genes thought to be downregulated in late stages are shown to persist and others 
thought to be upregulated are absent.  One possible answer is that many of the genes 
associated with metastatic potential may not undergo one-way modification of regulation and 
instead retain the potential to reverse changes in expression.   
 
Investigations into the gene expression signatures of melanoma cell lines taken from late stage 
tumors show that a given cell line is highly likely to express one of two major transcription 
programs.  It was also determined that the genes whose expression patterns respectively 
delineated the two signatures were likely involved in melanoma metastatic potential (Bittner 
et al., 2000; Hoek et al., 2006).  One of these signatures (identified by us as proliferative) has 
MITF and other melanocytic genes (e.g. TYR, DCT, MLANA) upregulated along with a 
number of additional neural crest-related factors (e.g. SOX10, TFAP1A, EDNRB), and this 
signature is associated with high rates of proliferation, low motility and sensitivity to growth 
inhibition by TGF.  A second signature (identified by us as invasive) downregulates these 
genes and instead upregulates others whose secreted products (e.g. INHBA, COL5A1, 
SERPINE1) are known to be involved in modifying the extracellular environment, and this 
signature is associated with lower rates of proliferation, high motility and resistance to growth 
inhibition by TGF.  Having identified these genes we found that many of the proliferative 
signature were common responders to Wnt signaling, and those of the invasive signature were 
TGF signal-driven, and we proposed that these signaling pathways are responsible for the 
different transcription signatures observed (Hoek et al., 2006).  Among genes comprising the 
invasive signature are several (e.g. WNT5A, DKK1 and CTGF) known to negatively regulate 
Wnt signaling (Ishitani et al., 2003; Mercurio et al., 2004; Zorn, 2001), suggesting that 
activation of TGF signaling may precipitate deactivation of Wnt signaling.  Similar cross-
talk opposition between TGF and Wnt signaling has already been noted in gastrointestinal 
cancer (Mishra et al., 2005).  This link between the signatures indicated to us that they may be 
reversible given appropriate signals, and further suggested that proliferation and invasion are 
program states which melanoma cells activate according to microenvironmental cues. 
 
The results of our in vitro proliferation and motility analyses were consistent with signature 
assignments inferred from earlier DNA microarray experiments (Hoek et al., 2006).  In order 
to immunohistochemically differentiate signatures in vivo we used nuclear Mitf as our marker 
for the proliferative signature and nuclear Ki67 antigen as a general indicator for proliferation 
activity.  We found in vitro that while both invasive and proliferative signature melanoma 
cells expressed Ki67 antigen, significantly more proliferative signature cells expressed it, 
correlating with the relative growth differences observed between proliferative and invasive 
cells in vitro.  The Ki67 antigen is preferentially expressed during late G1, S, G2 and M 
phases of the cell cycle and is not detected in G0 (Braun et al., 1988; Bruno and 
Darzynkiewicz, 1992), that Ki67 antigen may be an absolute requirement for cell proliferation 
was indicated by siRNA knockdown experiments in myeloma cells (Schluter et al., 1993).  
The role of Mitf in melanoma proliferation is less clear.  One report notes that Mitf expression 
in melanoma is suppressed by BRAF activation and increasing Mitf expression in this context 
is anti-proliferative (Wellbrock and Marais, 2005).  However, increasing Mitf expression in 
melanoma has also been shown to be a proliferative factor and is involved in Cdk2 production 
(Du and Fisher, 2002; Widlund et al., 2002).  Recent studies have shown that Mitf is also an 
indirect negative regulator of the p27Kip1 Cdk inhibitor, which would otherwise act to suppress 
Cdk2 activation and block G1/S transition (Carreira et al., 2006).  Our data also supports a 
proliferative role for Mitf in vitro as we find that Mitf-positive lines proliferate faster (Figure 
1) and express Ki67 antigen with greater frequency than Mitf-negative lines (Figure 2).  
 
We performed siRNA knockdown of Mitf in a proliferative signature cell line and show that 
this confers a phenotype observed in invasive signature line melanomas.  Proliferative 
signature cells are susceptible to TGF-mediated inhibition of proliferation, while invasive 
signature cells are not.  Several other studies also showed that aggressively invasive 
melanoma cells are resistant to TGF(Heredia et al., 1996; Krasagakis et al., 1994; Roberts et 
al., 1985).  Our DNA microarray data suggested that Mitf gene expression is central to the 
proliferative signature and may therefore have a role in mediating the growth-inhibitory 
response to TGF.  After knockdown of Mitf expression in a proliferative signature line the 
cells were less susceptible to TGF-mediated inhibition of proliferation (Figure 2).  
Experiments by others have shown that invasion through matrigel is increased in Mitf-
expressing melanoma cells treated with siRNA targeting Mitf (Carreira et al., 2006).  
Together these combined findings indicate that regulation of Mitf expression is critical to 
signature membership and supports our contention that in vivo changes in nuclear Mitf 
staining indicate proliferative/invasive signature switching. 
 
Our xenograft experiments showed that the proliferative and invasive gene expression 
signatures also correlated appropriately with tumor growth patterns.  Proliferative signature 
lines initiated tumors about two weeks after injection while invasive signature lines lay 
dormant for an average of eight weeks before tumor growth began (Figure 2).  While these 
and the in vitro experiments further support the different signature assignments to different 
melanoma cell lines, immunohistochemical examination of the tumors could not readily 
distinguish between them, rather they showed evidence for signature switching.  Comparison 
of in vitro Mitf staining patterns with in vivo Mitf staining patterns shows that resultant 
tumors deriving from either proliferative signature or invasive signature lines reveal the 
presence of both Mitf-positive and Mitf-negative melanoma cells (Figure 3).  Concurrently, 
Ki67 antigen staining, while found throughout the tumors, was significantly more frequent in 
regions positive for Mitf staining than in regions absent of Mitf.  Furthermore, the distribution 
of Mitf staining and increased frequency of Ki67 antigen positivity shows a distinctly 
peripheral pattern.  This suggests that melanoma cells proximal to the interface between host 
tissues and the tumor are actively undergoing increased rates of proliferation. 
 
The long lag-time for tumor initiation observed with invasive signature cells and the presence 
of Mitf-positive nuclei in resulting tumors indicate that tumor growth was probably preceded 
by a switch in some cells to the proliferative signature type.  Similar microenvironment-
driven signature switching has been shown previously in other experiments.  Recent studies 
investigating the effect of embryonic environments on melanoma cells has shown how these 
environments can affect the aggressive phenotype.  Kulesa and co-workers, using the 
aggressive C8161 melanoma line, showed that transplantation of C8161 cells into chick 
embryonic tissues stimulated re-expression of melanocytic markers similar to poorly 
aggressive cells (Kulesa et al., 2006).  Complimentary in vitro studies in which poorly 
aggressive cells, grown on 3D matrices preconditioned by aggressive lines, showed 
upregulation of extracellular matrix modifying genes and increased invasive ability (Seftor et 
al., 2006).  Additional experiments in zebrafish revealed that in embryonic environments 
inhibition of the morphogen Nodal switched melanoma cells to a less aggressive phenotype, 
suggesting that Nodal signaling (which acts through TGF family receptors) was important to 
maintaining aggressive phenotypes in melanoma cells (Topczewska et al., 2006).  Signature 
switching of cells in response to the microenvironment would explain why our xenograft 
tumors deriving from different signature lines were immunohistochemically indistinguishable.  
That rapidly proliferating cells are found closer to the periphery of growing tumors also 
supports a role for the microenvironmental determination of activity. 
 
These data are critical pieces of the melanoma progression puzzle because they suggest not 
only that invasion and proliferation are divisible aspects of metastatic potential, but that these 
different transcriptional states are interchangeable programs between which melanoma cells 
oscillate during progression in response to changing microenvironmental cues (Figure 5).  
What these microenvironmental cues precisely are remains unknown, but there is growing 
evidence that hypoxia may be one (Holmquist et al., 2006) and inflammation another (de 
Visser et al., 2006).  The relevance of this model to clinical aspects of melanoma is that it may 
explain why metastatic melanoma is so resistant to chemo- and immunotherapeutic strategies.  
The heterogeneity inherent in tumors containing melanoma cells whose transcriptional 
patterns and biological activities are dependent on the microenvironment suggests that while 
proliferating cells are susceptible to chemotherapy there are a population of cells which, 
though not proliferating, have the capacity to switch to a proliferative program and 
successfully drive tumor progression once therapy has ceased.  By the same token, targeted 
therapies which frequently aim for melanocytic antigen-expressing cells would not recognize 
cells whose expression programs are dedifferentiated from the melanocytic phenotype, cells 
who will serve to repopulate that phenotype at a later time. 
Experimental procedures 
Melanoma tissues and lines 
Melanoma cell cultures were established from surplus material from cutaneous melanoma 
metastases removed by surgery after having obtained written informed consent of the patient.  
Clinical diagnosis was confirmed by histology and immunohistochemistry.  Melanoma cells 
were released from tissue sections and grown as previously described (Geertsen et al., 1998).  
Cell lines were chosen according to their transcription pattern signatures as previously 
described (Hoek et al., 2006).  Two proliferative signature (M980513, M000907) and two 
invasive signature (M991121, M010308) melanoma lines were used.  Paraffin-embedded 
examples of cutaneous metastases of melanoma were also selected for comparative analysis.  
 
In vitro motility and proliferation assays 
For the motility assays 2 x 104 melanoma cells were seeded on 8M transwell microporous 
filters (Becton Dickinson, Franklin Lakes, NJ) in 200 μl RPMI.  As a chemoattractant RPMI 
containing 10% FCS was added to the lower chamber. After 18 hours of incubation cells on 
the upper side of the filter were removed with cotton swab.  The membrane was then stained 
using a standard hematoxylin and eosin protocol and the cells were counted under a light 
microscope.  For the proliferation assay melanoma cells were seeded to a density of 5 x 104 in 
each well of a six-well plate.  After 24, 72 and 96 hours cells were counted in a Neubauer 
chamber to estimate cell-doubling times.   
 
Recombinant adenovirus vector and siRNA 
Recombinant first-generation, E1/E3-deleted Ad5-based vectors Ad-H1-siMitf and Ad-H1-
siControl were generated as described previously(Hemmi et al., 1998). Briefly, homologous 
recombination was performed in human embryonic retinoblast line 911 cells between a 
transfer plasmid pAd-H1-siMitf encoding the Mitf-specific siRNA sequence under the control 
of the H1 promoter and a genomic ClaI DNA fragment isolated from AdMLP-lacZ. To 
construct pAd-H1-siMitf, the CMV promoter of pAd-CMV∆lacZ-lnk1 was replaced with the 
H1 promoter (Hasuwa et al., 2002). The H1 promoter fragment was PCR-amplified from 
genomic DNA of human 293T cells and cloned into SfiI/BamHI-restricted pAd-CMV∆lacZ-
Ink1. Following this, oligonucleotides for the silencing cassette(Saydam et al., 2005) 
containing a 19-nucleotide siRNA sequence targeting Mitf (Busca et al., 2005) were cloned 
into NheI/SalI-restricted pAd-H1∆lacZ-lnk1 (Ad-H1-siMitf). For a mock control (Ad-H1-
siControl), the siRNA sequence of Mitf was scrambled and blasted to ensure no human 
sequence is targeted. Recombinant adenoviruses were plaque-purified, amplified, and CsCl 
purified. Viral titers were determined by plaque assay, using 911 cells, and were 1.8 x 1010 
PFU/ml for Ad-H1-siMitf and 1.3 x 1010 PFU/ml for Ad-H1-siControl.  
 
Transfection and TGF challenge assay 
Melanoma cells were seeded to a density of 4 x 104 cells in a 24-well plate one day before 
infection. The next day medium was changed to RPMI containing 2% FCS and cells were 
either infected with virus particles carrying the pAd-H1-siMitf or pAd-H1-siControl.  For 
assessment of susceptibility to growth inhibition by TGF, cells were challenged with 5 ng/ml 
recombinant TGF (Biosource, Camarillo, CA) 24 hours after virus transduction.  After a 
further 56 hours cell growth was estimated using a standard MTT assay.  
 
Western blot analyses 
Cells were solubilized in lysis buffer containing 20 mM Tris-HCl pH 7.5, 1% TritonX-100, 
150 mM NaCl, 10% glycerol and Complete mini protease inhibitor (Roche Diagnostics 
GmbH, Mannheim, Germany).  Proteins were separated on a NuPAGE 10% Bis-Tris gel 
(Invitrogen, Carlsbad, CA) under denaturing and reducing conditions followed by transfer 
onto a Nitrocellulose membrane (Invitrogen).  Mitf protein was detected with a mouse anti-
Mitf MAb (LabVision, CA, USA) diluted 1:100 in 3% BSA at 4oC overnight. Secondary 
rabbit-anti-mouse antibodies (Abcam, Cambridge, UK) conjugated with peroxidase was used 
at a dilution of 1:10000. Detection by chemiluminescence used an enhanced 
chemiluminescence system (GE Healthcare, Buckinghamshire, UK). 
 
Xenografts 
For each melanoma line a total of 3 x 106 cells were injected into both flanks of eight-week 
old female athymic nude mice.  Mice were kept in individually ventilated cages for a 
maximum of 75 days post injection.  Size and mass of tumors was recorded once every 3-7 
days until linear growth was detected, after which measurements were taken every 1-2 days.  
If at least one xenograft tumor reached 1 cm3 the mouse was sacrificed and tumors removed.  
If the condition of the mouse deteriorated (e.g. listlessness, loss of weight) the mouse was 
sacrificed and tumors removed.  All remaining mice were sacrificed on the 75th day and 
tumors removed.  Effective tumor initiation time was calculated on the day tumor volume 
reached 100 mm3.  Tumors not reaching 100 mm3 within 75 days were not considered. 
 
Immunohistochemistry 
Cell lines were prepared for immunohistochemistry as follows.  Briefly, cells were cultured, 
washed in PBS (Biochrom, Berlin, Germany) and then put into suspension by incubating in 2 
mL trypsin/EDTA solution (Biochrom) at 37° C.  Trypsin was inactivated by adding 18 mL of 
FCS-containing growth medium.  Cell suspensions were centrifuged for 5 min at 2000 rpm.  
After removing the supernatant, four drops of plasma were added to the pellet and the solution 
was mixed.  One drop of thrombin was added and after five minutes the coagulated material 
was encapsulated for fixation in 4% formalin and embedded in paraffin.  Excised xenograft 
samples were fixed in 4% formalin and embedded in paraffin.  Slides were cut from paraffin 
blocks and immunohistochemically stained using the alkaline phosphatase-anti-alkaline 
phosphatase technique and counter-stained using hematoxylin.  Antibodies used were directed 
against Mitf or Ki-67 (DakoCytomation, Glostrup, Denmark).  Counting of stained and 
unstained nuclei was done on a PC using the free UTHSCSA ImageTool program (developed 
at the University of Texas Health Science Center at San Antonio, Texas and available from 
the Internet by anonymous FTP from ftp://maxrad6.uthscsa.edu).  
 
Statistical analysis 
For all quantitative sample comparisons Student’s two-sample heteroscedastic t-test was used 
to calculate a t-statistic for comparison against a significance cutoff of p = 0.05. 
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FIGURE LEGENDS 
 
Figure 1.  In vitro correlations with gene expression signatures.  M980513 and M000907  
proliferative signature (Pro) melanoma lines, as well as M991121 and M010308 invasive 
signature (Inv) melanoma lines, were chosen for this study.  (A) A gene expression heatmap, 
generated by clustering samples based on the normalized expression of 105 metastatic 
potential genes, shows the subtype-specific signatures for Pro and Inv signature melanoma 
lines.  In vitro growth (B) and motility (C) experiments correlate appropriately with 
proliferative and invasive signature assignments.  Error bars indicate standard deviation.  
 
Figure 2.  siRNA knockdown of Mitf protects against TGF-mediated growth inhibition.  
(A) siRNA-mediated knockdown of Mitf in a proliferative signature melanoma cell line was 
confirmed by Western blot analysis.  (B) TGF-susceptibility experiments show that Mitf 
knockdown promotes significant (p < 0.03) resistance to TGF-mediated growth inhibition in 
a proliferative signature melanoma cell line. 
 
Figure 3.  Immunohistochemical marker correlations with gene expression signatures.  
Immunohistochemical analysis of paraffin-embedded cell lines shows that proliferative and 
invasive signature lines have differential staining for Mitf (93% and 0%, respectively) and 
Ki67 antigen (92% and 45%, respectively).  
 
Figure 4.  Xenograft tumor growth.  Human melanoma cell lines were injected into both 
flanks of immunocompromised nude mice.  Proliferation of melanoma cells led to tumor 
growth which was monitored daily.  Proliferative melanoma cells (Pro) formed tumors 
rapidly, while invasive melanoma cells (Inv) took weeks longer to initiate tumor growth. 
 
Figure 5.  Immunohistochemistry of melanoma xenograft tumors.  Cell lines were 
injected into the flanks of immunocompromised nude mice and allowed to grow tumors for a 
maximum of 75 days.  After a tumor had formed it was removed and subjected to 
immunohistochemical analysis.  (A) Tumor resulting from an invasive signature melanoma 
(M010308), with two separate fields (1 and 2) examined in more detail.  (B and C) Mitf and 
Ki67 stains of field A1.  (D and E) Mitf and Ki67 stains of field A2.  (F) Tumor resulting 
from a proliferative signature melanoma (M980513) line.  (G and H) Mitf and Ki67 stains of 
field F1.  (I and J) Mitf and Ki67 stains of field F2. 
 
Figure 6.  An integrated model for gene regulation of melanoma metastatic potential and 
progression.  Early phase melanoma cells expressing the “proliferative signature” gene set 
proliferate to form the primary lesion.  Following this an unknown signal switch, likely 
brought about by altered microenvironmental conditions (e.g. hypoxia), gives rise to cells 
with a significantly different “invasive signature” gene set.  Invasive signature cells escape 
and, upon reaching a suitable distal site, revert to the proliferative state and nucleate a new 
metastasis where the cycle is repeated.  Each switch in phenotype (state change) is 
accompanied by an exchange in expressed gene sets from proliferative to invasive and vice 
versa. 
